Posted by Michael Wonder on 10 Sep 2020
FDA approves Trelegy Ellipta as the first once daily single inhaler triple therapy for the treatment of both asthma and COPD in the US
9 September 2020 - New asthma indication for Trelegy Ellipta introduces an important option for patients to the current treatment paradigm.
GlaxoSmithKline and Innoviva announced the US FDA has approved a new indication for Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol) for the treatment of asthma in patients aged 18 years and older adding to its current license for use in patients with chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is not indicated for relief of acute bronchospasm.
The FDA approved strength for both COPD and asthma is fluticasone furoate / umeclidinium / vilanterol 100/62.5/25 mcg. There is an additional strength for asthma alone which is fluticasone furoate / umeclidinium / vilanterol 200/62.5/25 mcg.
